Henry Schein (NASDAQ:HSIC) Stock Rating Upgraded by ValuEngine

Henry Schein (NASDAQ:HSIC) was upgraded by equities research analysts at ValuEngine from a “sell” rating to a “hold” rating in a research note issued to investors on Monday, February 4th.

Several other equities analysts have also weighed in on HSIC. BidaskClub upgraded shares of Henry Schein from a “buy” rating to a “strong-buy” rating in a report on Thursday, November 1st. UBS Group initiated coverage on shares of Henry Schein in a report on Thursday, January 17th. They issued a “sell” rating and a $73.00 target price on the stock. Barrington Research boosted their target price on shares of Henry Schein from $92.00 to $96.00 and gave the company an “outperform” rating in a report on Thursday, November 8th. Morgan Stanley boosted their target price on shares of Henry Schein from $65.00 to $66.00 and gave the company an “underweight” rating in a report on Tuesday, October 9th. Finally, Goldman Sachs Group initiated coverage on shares of Henry Schein in a report on Saturday, October 20th. They issued a “hold” rating and a $78.00 target price on the stock. Seven investment analysts have rated the stock with a sell rating, six have assigned a hold rating and six have issued a buy rating to the company’s stock. Henry Schein presently has a consensus rating of “Hold” and a consensus target price of $79.87.

HSIC traded up $0.77 on Monday, reaching $60.07. 1,692,716 shares of the company’s stock were exchanged, compared to its average volume of 2,300,315. The firm has a market capitalization of $9.09 billion, a PE ratio of 14.54, a PEG ratio of 2.17 and a beta of 0.89. Henry Schein has a twelve month low of $57.76 and a twelve month high of $91.35. The company has a current ratio of 1.30, a quick ratio of 0.70 and a debt-to-equity ratio of 0.28.

Henry Schein (NASDAQ:HSIC) last posted its quarterly earnings results on Wednesday, February 20th. The company reported $1.12 earnings per share for the quarter, topping analysts’ consensus estimates of $1.11 by $0.01. The firm had revenue of $3.38 billion for the quarter, compared to analyst estimates of $3.46 billion. Henry Schein had a net margin of 4.06% and a return on equity of 19.86%. Henry Schein’s quarterly revenue was up 1.7% on a year-over-year basis. During the same period in the previous year, the business posted $0.97 earnings per share. As a group, analysts predict that Henry Schein will post 3.44 earnings per share for the current fiscal year.

Henry Schein declared that its Board of Directors has approved a stock repurchase program on Thursday, December 13th that authorizes the company to repurchase $400.00 million in outstanding shares. This repurchase authorization authorizes the company to repurchase up to 3.1% of its stock through open market purchases. Stock repurchase programs are often an indication that the company’s board believes its stock is undervalued.

In related news, CEO Stanley M. Bergman sold 69,000 shares of the company’s stock in a transaction that occurred on Friday, December 7th. The shares were sold at an average price of $86.32, for a total transaction of $5,956,080.00. Following the sale, the chief executive officer now directly owns 240,096 shares of the company’s stock, valued at approximately $20,725,086.72. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CFO Steven Paladino sold 21,110 shares of the company’s stock in a transaction that occurred on Monday, December 3rd. The stock was sold at an average price of $90.06, for a total transaction of $1,901,166.60. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 97,535 shares of company stock worth $8,483,620. Company insiders own 1.15% of the company’s stock.

Institutional investors and hedge funds have recently made changes to their positions in the stock. Bell Asset Management Ltd increased its stake in Henry Schein by 5.0% during the 3rd quarter. Bell Asset Management Ltd now owns 114,872 shares of the company’s stock worth $9,768,000 after buying an additional 5,508 shares during the period. JLB & Associates Inc. increased its position in shares of Henry Schein by 1.9% in the 3rd quarter. JLB & Associates Inc. now owns 55,818 shares of the company’s stock valued at $4,746,000 after purchasing an additional 1,051 shares during the last quarter. Oppenheimer Asset Management Inc. increased its position in shares of Henry Schein by 6.1% in the 3rd quarter. Oppenheimer Asset Management Inc. now owns 63,284 shares of the company’s stock valued at $5,381,000 after purchasing an additional 3,642 shares during the last quarter. Steinberg Global Asset Management increased its position in shares of Henry Schein by 43.4% in the 4th quarter. Steinberg Global Asset Management now owns 32,661 shares of the company’s stock valued at $2,565,000 after purchasing an additional 9,879 shares during the last quarter. Finally, Coastline Trust Co increased its position in shares of Henry Schein by 4.1% in the 3rd quarter. Coastline Trust Co now owns 24,110 shares of the company’s stock valued at $2,050,000 after purchasing an additional 940 shares during the last quarter.

Henry Schein Company Profile

Henry Schein, Inc provides health care products and services to dental practitioners and laboratories, animal health clinics, physician practices, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.

Featured Article: What Are Treasury Bonds?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Henry Schein (NASDAQ:HSIC)

Receive News & Ratings for Henry Schein Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Henry Schein and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply